SecBot SecBot
PRESS-RELEASE ·Filed Aug 13, 2026

KOD

Kodiak Sciences Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The September 2026 DAYBREAK readout is the dominant near-term catalyst, positive non-inferiority data for Zenkuda or KSI-501 vs aflibercept could unlock a multi-billion dollar anti-VEGF market opportunity. Monitor for any pre-read or data leaks ahead of the expected topline release. Cash runway into 2027 provides a buffer, but a negative readout would likely force a dilutive financing or strategic alternative.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

KOD drug pipeline →

KSI-101

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
Next catalyst
None dated

What to watchThe December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$41.35
T+0 close · Aug 13, 2026 · via day close
Latest settled
+159.01%
T+60 · $107.10
Vs SPY
+162.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $41.35entry
  2. T+1 · 3mo ago −0.89%α −0.42% · $40.98
  3. T+5 · 3mo ago −7.30%α −5.94% · $38.33
  4. T+20 · 2mo ago −19.85%α −17.86% · $33.14
  5. T+60 · 8d ago +159.01%α +162.05% · $107.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, with R&D spending up 31% to $56.1M as clinical activities ramp. The stock's primary catalyst is the upcoming September 2026 DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in wet AMD, followed by December 2026 PEAK data for KSI-101 in MESI. Cash of $125.9M is expected to fund operations into 2027, but the widening loss and lack of revenue make this a binary event-driven pre-commercial biotech story.

Key Financial Metrics

EPS
−$1.05
est −$0.97 · -8.3%
Rating
in line

Key Facts

  • Net loss Q2 2026: $65.6M ($1.05/share) vs $54.3M ($1.03/share) in Q2 2025
  • Cash and cash equivalents: $125.9M as of June 30, 2026
  • R&D expenses: $56.1M in Q2 2026, up from $42.8M in Q2 2025
  • DAYBREAK Phase 3 topline data (Zenkuda & KSI-501) expected September 2026
  • PEAK Phase 3 Pivotal Analysis 1 topline data (KSI-101) expected December 2026
  • ALTO Phase 3 study (KSI-501 in DME) now enrolling patients
  • BLA preparation activities for Zenkuda ongoing
  • No revenue reported; company is pre-commercial

Financial Impact

Net loss widened by $11.3M YoY to $65.6M; cash burn rate ~$42M/quarter based on $125.9M cash vs $209.9M at year-end 2025

net losscash and cash equivalentsR&D expenses

Risk Factors

  • Phase 3 DAYBREAK study fails to meet non-inferiority primary endpoint
  • Cash runway only into 2027; potential need for dilutive financing if development timelines slip
  • Regulatory or manufacturing delays for Zenkuda BLA submission
  • Competitive landscape: existing anti-VEGF therapies (aflibercept, faricimab) with established market positions

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302851311

Track record

13 reports on KOD

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $111.19 −5.97% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $111.19 −1.54% settles Dec 15
  3. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $111.19 +0.00% settles Dec 14
  4. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $111.19 +3.82% settles Dec 8
  5. Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $111.19 −26.76% settles Nov 18
  6. Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
  7. Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
  8. Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $111.19 +23.65% ▼ −0.36% −0.32% vs SPY
  9. Aug 13, 202613w ago 8-K Neutral 4/10 No price data
  10. Aug 13, 202613w ago Press Release Neutral 6/10 Viewing Entry $41.35 to $33.14 Now $111.19 +168.90% ▼ −19.85% −17.86% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (13h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026